Some adults with type 2 diabetes can reduce or stop scheduled mealtime insulin after starting a GLP-1 medicine under medical supervision. The trials tested this strategy while keeping basal insulin in the treatment plan. People with type 1 diabetes still need insulin [1] [3].
What’s approved and how treatment changes are made
The FDA label for Ozempic injection includes improving blood sugar in adults with type 2 diabetes. Our Wegovy and Ozempic comparison explains how the labeled uses differ. Ozempic’s label does not list insulin replacement as a distinct indication[4]. The ADA and EASD advise closer monitoring when a potent medicine is added to insulin, and some people still need mealtime insulin to reach glucose goals[5]. Ask your diabetes care team before stopping or changing insulin.
What changing mealtime insulin did in the trials
The trials used clinical protocols to withdraw, replace or substantially reduce scheduled mealtime insulin. The pooled difference in HbA1c change was −0.08 percentage points (95% confidence interval −0.28 to 0.12) with the GLP-1 strategy versus continued intensive insulin treatment. The analysis did not establish that the strategies were equivalent [1].
Compared with continuing the insulin regimen, the GLP-1 strategy was associated with −4.94 kg in body weight (95% confidence interval −7.37 to −2.51 kg) and −33.32 units per day in total insulin (−52.23 to −14.41). These are differences between groups[1].
In one of the trials, TRANSITION-T2D, 60 adults whose type 2 diabetes was already reasonably controlled were assigned to semaglutide plus basal insulin or to continue multiple daily insulin injections. At 26 weeks, 97.5% of the semaglutide group had stopped scheduled mealtime insulin. The trial was small and enrolled selected patients [2].
What the trials tell us about cost
Our guide to GLP-1 insurance coverage explains why out-of-pocket costs can vary by plan and indication. These trials do not establish what either treatment will cost a particular person.